Gamifant
Term · Oncology and biomedicine · MLC-T-ONC-003395
A drug used to treat a rare immune system disorder called primary hemophagocytic lymphohistiocytosis (HLH). It is used in patients whose disease came back, got worse, did not get better, or cannot be treated with other therapy. It is also being studied in the treatment of other conditions. Gamifant binds to an immune system protein called interferon gamma, which is found at higher than normal levels in patients with HLH. This may help lower the body’s immune response and reduce inflammation. Gamifant is a type of monoclonal antibody. Also called emapalumab.
| Identifier | MLC-T-ONC-003395 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | emapalumab |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-003395",
"term": "Gamifant",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat a rare immune system disorder called primary hemophagocytic lymphohistiocytosis (HLH). It is used in patients whose disease came back, got worse, did not get better, or cannot be treated with other therapy. It is also being studied in the treatment of other conditions. Gamifant binds to an immune system protein called interferon gamma, which is found at higher than normal levels in patients with HLH. This may help lower the body’s immune response and reduce inflammation. Gamifant is a type of monoclonal antibody. Also called emapalumab.",
"synonyms": [
"emapalumab"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/gamifant/"
}
Record 7,780 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.